{"id":"mefloquine-plus-artesunate","safety":{"commonSideEffects":[{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Vomiting"},{"rate":null,"effect":"Dizziness"},{"rate":null,"effect":"Neuropsychiatric effects (mefloquine-related)"},{"rate":null,"effect":"Abdominal pain"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Mefloquine acts as a blood schizonticide, disrupting the malaria parasite's ability to metabolize hemoglobin and maintain ion balance within infected red blood cells. Artesunate, a fast-acting artemisinin derivative, generates reactive oxygen species that damage parasite proteins and DNA. The combination leverages their different mechanisms and pharmacokinetics to provide rapid parasite clearance and reduce the emergence of drug-resistant strains.","oneSentence":"This combination uses mefloquine (a quinoline antimalarial) and artesunate (an artemisinin derivative) to kill malaria parasites through complementary mechanisms that reduce drug resistance.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:20:34.301Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Uncomplicated Plasmodium falciparum malaria"},{"name":"Malaria in endemic regions with artemisinin resistance"}]},"trialDetails":[{"nctId":"NCT03923725","phase":"PHASE3","title":"A Trial to Compare the Efficacy, Safety and Tolerability of Combinations of 3 Anti-malarial Drugs Against Combina-tions of 2 Anti-malarial Drugs.","status":"COMPLETED","sponsor":"University of Oxford","startDate":"2020-09-01","conditions":"Plasmodium Falciparum Malaria (Uncomplicated)","enrollment":2583},{"nctId":"NCT05690841","phase":"PHASE3","title":"FocaL Mass Drug Administration for Vivax Malaria Elimination","status":"RECRUITING","sponsor":"University of California, San Francisco","startDate":"2024-10-14","conditions":"Plasmodium Vivax Malaria, Malaria","enrollment":7530},{"nctId":"NCT03939104","phase":"PHASE3","title":"A Trial to Compare the Efficacy, Safety and Tolerability of Combinations of 3 Anti-malarial Drugs Against Combinations of 2 Anti-malarial Drugs (Asia)","status":"COMPLETED","sponsor":"University of Oxford","startDate":"2021-06-30","conditions":"Plasmodium Falciparum Malaria (Uncomplicated)","enrollment":103},{"nctId":"NCT05052502","phase":"NA","title":"Targeting High Risk Populations With Enhanced Reactive Focal Mass Drug Administration in Thailand","status":"UNKNOWN","sponsor":"University of California, San Francisco","startDate":"2020-11-01","conditions":"Plasmodium Falciparum Malaria, Plasmodium Vivax Malaria","enrollment":49118},{"nctId":"NCT00403260","phase":"PHASE3","title":"Pyronaridine - Artesunate (3:1) Versus Mefloquine Plus Artesunate in Plasmodium Falciparum Malaria Patients","status":"COMPLETED","sponsor":"Medicines for Malaria Venture","startDate":"2007-01","conditions":"Falciparum Malaria","enrollment":1271},{"nctId":"NCT03083847","phase":"PHASE1","title":"Dose Escalation PfSPZ-CVac","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2017-06-05","conditions":"Malaria","enrollment":55},{"nctId":"NCT02653898","phase":"PHASE4","title":"Malaria Elimination Pilot Study in Military Forces in Cambodia","status":"UNKNOWN","sponsor":"Armed Forces Research Institute of Medical Sciences, Thailand","startDate":"2016-01","conditions":"Malaria, Parasitic Diseases","enrollment":1050},{"nctId":"NCT03726593","phase":"PHASE4","title":"Drug Combinations of Atovaquone-Proguanil (AP) With ACT","status":"UNKNOWN","sponsor":"Armed Forces Research Institute of Medical Sciences, Thailand","startDate":"2018-10-04","conditions":"Plasmodium Falciparum Malaria (Drug Resistant)","enrollment":252},{"nctId":"NCT02612545","phase":"PHASE1","title":"Efficacy, Safety, and Tolerability of Dihydroartemisinin-piperaquine + Mefloquine Compared to Dihydroartemisinin-piperaquine or Artesunate-mefloquine in Patients With Uncomplicated Falciparum Malaria in Cambodia","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2015-11-20","conditions":"Acute Falciparum Malaria","enrollment":216},{"nctId":"NCT00936767","phase":"PHASE2, PHASE3","title":"Artemisone for the Treatment of Uncomplicated Falciparum Malaria in Western Cambodia","status":"WITHDRAWN","sponsor":"University of Oxford","startDate":"2010-10","conditions":"Uncomplicated Falciparum Malaria","enrollment":""},{"nctId":"NCT02453308","phase":"PHASE2, PHASE3","title":"A Study by the Tracking Resistance to Artemisinin Collaboration (TRAC)","status":"COMPLETED","sponsor":"University of Oxford","startDate":"2015-08","conditions":"Malaria, Falciparum","enrollment":1110},{"nctId":"NCT00493363","phase":"NA","title":"Clinical Investigation of In-vivo Susceptibility of P.Falciparum to Artesunate in Western Cambodia","status":"COMPLETED","sponsor":"University of Oxford","startDate":"2007-06","conditions":"Falciparum Malaria","enrollment":40},{"nctId":"NCT01976780","phase":"PHASE4","title":"In Vivo and In Vitro Efficacy of Artemisinin Combination Therapy","status":"COMPLETED","sponsor":"Global Emerging Infections Surveillance and Response System","startDate":"2013-06","conditions":"Malaria","enrollment":118},{"nctId":"NCT02974348","phase":"PHASE3","title":"Antimalaria Drugs Susceptibility Testing for an Effective Management of Infected Patients in Sub-Sahara Africa","status":"COMPLETED","sponsor":"University of Bamenda","startDate":"2013-01","conditions":"Drug Resistant Malaria Due to Plasmodium Falciparum","enrollment":300},{"nctId":"NCT00852423","phase":"PHASE3","title":"Safe and Efficacious Artemisinin-based Combination Treatments for African Pregnant Women With Malaria","status":"COMPLETED","sponsor":"Institute of Tropical Medicine, Belgium","startDate":"2010-06","conditions":"Malaria in Pregnancy","enrollment":3428},{"nctId":"NCT02052323","phase":"PHASE4","title":"Harmonized AS/MQ Efficacy Study - Thailand","status":"COMPLETED","sponsor":"Armed Forces Research Institute of Medical Sciences, Thailand","startDate":"2013-10","conditions":"Malaria","enrollment":48},{"nctId":"NCT01350856","phase":"PHASE4","title":"Tracking Resistance to Artemisinin (TRAC)","status":"COMPLETED","sponsor":"University of Oxford","startDate":"2011-05","conditions":"Falciparum Malaria","enrollment":1700},{"nctId":"NCT01144702","phase":"PHASE2, PHASE3","title":"Effectiveness of the Association Artesunate and Mefloquine in the Treatment of Malaria by Plasmodium Falciparum","status":"COMPLETED","sponsor":"Oswaldo Cruz Foundation","startDate":"2010-11","conditions":"Falciparum Malaria","enrollment":163},{"nctId":"NCT01708876","phase":"PHASE3","title":"P. Knowlesi Trial of Artesunate-mefloquine Versus Chloroquine","status":"COMPLETED","sponsor":"Menzies School of Health Research","startDate":"2012-10","conditions":"Uncomplicated Plasmodium Knowlesi Malaria","enrollment":250},{"nctId":"NCT01319448","phase":"PHASE1, PHASE2","title":"Intermittent Preventive Treatment for Malaria in Patient With Sickle Cell Disease","status":"COMPLETED","sponsor":"London School of Hygiene and Tropical Medicine","startDate":"2011-09","conditions":"Malaria, Sickle Cell Crisis","enrollment":270},{"nctId":"NCT01939886","phase":"PHASE3","title":"Treatment Efficacy and Malaria TRANSmission After Artemisinin Combination Therapy 2 (TRANSACT2)","status":"COMPLETED","sponsor":"London School of Hygiene and Tropical Medicine","startDate":"2013-04","conditions":"Malaria","enrollment":219},{"nctId":"NCT00243737","phase":"PHASE2","title":"Efficacy, Safety and Pharmacokinetic of ArtequinTM P. Falciparum Malaria","status":"COMPLETED","sponsor":"Albert Schweitzer Hospital","startDate":"2005-10","conditions":"Malaria","enrollment":70},{"nctId":"NCT00164216","phase":"","title":"Efficacy and Effectiveness of Combined Therapy for Uncomplicated Malaria Treatment in Peru","status":"COMPLETED","sponsor":"Centers for Disease Control and Prevention","startDate":"2005-03","conditions":"Malaria Falciparum","enrollment":208},{"nctId":"NCT01659281","phase":"NA","title":"Efficacy of Artesunate-Mefloquine Combination Therapy in Trat Province, Thailand","status":"COMPLETED","sponsor":"Armed Forces Research Institute of Medical Sciences, Thailand","startDate":"2007-09","conditions":"Plasmodium Falciparum Malaria","enrollment":13},{"nctId":"NCT01082731","phase":"PHASE4","title":"Efficacy of Artemisinin Combination Therapies for the Treatment of Uncomplicated P. Falciparum in Pregnancy in Brazil","status":"TERMINATED","sponsor":"Centers for Disease Control and Prevention","startDate":"2010-11","conditions":"Malaria","enrollment":6},{"nctId":"NCT01107145","phase":"PHASE4","title":"Efficacy of Artemisinin Combination Therapies for the Treatment of Uncomplicated P. Vivax in Pregnancy in Brazil (PAACT-PV)","status":"TERMINATED","sponsor":"Centers for Disease Control and Prevention","startDate":"2011-02","conditions":"Plasmodium Vivax Malaria","enrollment":16},{"nctId":"NCT01082718","phase":"PHASE2, PHASE3","title":"Pharmacokinetics of Mefloquine-Artesunate in Pregnant Women With Uncomplicated Plasmodium Falciparum Infection","status":"WITHDRAWN","sponsor":"Centers for Disease Control and Prevention","startDate":"2010-03","conditions":"Malaria, Pregnancy","enrollment":""},{"nctId":"NCT00373607","phase":"PHASE3","title":"Efficacy and Safety of Dihydroartemisinin/Piperaquine (Artekin®) for the Treatment of Uncomplicated Malaria in Peru","status":"COMPLETED","sponsor":"Institute of Tropical Medicine, Belgium","startDate":"2003-07","conditions":"Malaria","enrollment":522},{"nctId":"NCT00978172","phase":"PHASE4","title":"Safety and Efficacy Study of Artesunate and Mefloquin in Children With Uncomplicated Malaria","status":"COMPLETED","sponsor":"Mepha Ltd.","startDate":"2007-12","conditions":"Malaria","enrollment":220},{"nctId":"NCT00902811","phase":"PHASE4","title":"Effectiveness of Artemisinin Combination Regimens in Falciparum Malaria","status":"UNKNOWN","sponsor":"Medecins Sans Frontieres, Netherlands","startDate":"2008-12","conditions":"Uncomplicated Falciparum Malaria","enrollment":600},{"nctId":"NCT00544024","phase":"","title":"Mefloquine Bioequivalence Among 3 Commercially Available Tablets.","status":"COMPLETED","sponsor":"Centers for Disease Control and Prevention","startDate":"2004-03","conditions":"Malaria","enrollment":39}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":83,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Mefloquine plus artesunate","genericName":"Mefloquine plus artesunate","companyName":"Medicines for Malaria Venture","companyId":"medicines-for-malaria-venture","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This combination uses mefloquine (a quinoline antimalarial) and artesunate (an artemisinin derivative) to kill malaria parasites through complementary mechanisms that reduce drug resistance. Used for Uncomplicated Plasmodium falciparum malaria, Malaria in endemic regions with artemisinin resistance.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}